Skip to main content
Premium Trial:

Request an Annual Quote

ABI, HTS Biosystems, Mitsubishi Chemical in SPR Distribution Agreement

NEW YORK, April 7 - Applied Biosystems, HTS Biosystems, and Mitsubishi Chemical today announced a distribution agreement for a next-generation surface-plasmon resonance (SPR) system currently under development at HTS.

 

Under the agreement, Applied Biosystems Japan, a division of ABI, will be the exclusive distributor of the SPR system, which is designed to profile and characterize biomolecular interactions. The three companies also plan to co-develop new applications for the system, which ABI is targeting for worldwide commercial release by the mid-2003.

 

In 2000, HTS Biosystems granted Mitsubishi Chemical rights to distribute the SPR system once commercialized in Japan; and in April 2002, HTS and ABI entered a licensing and supply agreement to develop and commercialize the technology. Under the new agreement, HTS and Mitsubishi Chemical have granted ABI Japan exclusive distribution rights.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.